These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 23465058

  • 1. OnabotulinumtoxinA for treatment of chronic migraine: the unblinding problem.
    Solomon S.
    Headache; 2013 May; 53(5):824-6. PubMed ID: 23465058
    [No Abstract] [Full Text] [Related]

  • 2. Botulinum toxin for chronic migraine.
    Med Lett Drugs Ther; 2011 Jan 24; 53(1356):7-8. PubMed ID: 21252842
    [No Abstract] [Full Text] [Related]

  • 3. OnabotulinumtoxinA for chronic migraine.
    Blumenfeld A, Evans RW.
    Headache; 2012 Jan 24; 52(1):142-8. PubMed ID: 22268776
    [No Abstract] [Full Text] [Related]

  • 4. OnabotulinumtoxinA for the treatment of chronic migraine not quite there. .
    Torgovnick J.
    Cephalalgia; 2011 Feb 24; 31(3):377; author reply 378-9. PubMed ID: 21098110
    [No Abstract] [Full Text] [Related]

  • 5. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.
    J Neurol Sci; 2013 Aug 15; 331(1-2):48-56. PubMed ID: 23790235
    [Abstract] [Full Text] [Related]

  • 6. Onabotulinumtoxin [corrected] A (Botox).
    Tepper D.
    Headache; 2014 Apr 15; 54(4):787-8. PubMed ID: 24697235
    [No Abstract] [Full Text] [Related]

  • 7. Chronic migraine: a therapeutic challenge for clinicians.
    Irimia P, Carmona-Abellán M, Martínez-Vila E.
    Expert Opin Emerg Drugs; 2012 Dec 15; 17(4):445-7. PubMed ID: 22998764
    [Abstract] [Full Text] [Related]

  • 8. OnabotulinumtoxinA for treatment of chronic migraine: a response.
    Dodick DW, Turkel CC, Degryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF.
    Headache; 2011 Jun 15; 51(6):1005-8. PubMed ID: 21592099
    [No Abstract] [Full Text] [Related]

  • 9. Licence for Botox in so-called chronic migraine.
    Olesen J, Tfelt-Hansen P.
    Lancet; 2010 Nov 27; 376(9755):1825-6; discussion 1826. PubMed ID: 21111904
    [No Abstract] [Full Text] [Related]

  • 10. Can Botulinum Toxin Help Prevent Migraine in Adults?: A Cochrane Review Summary With Commentary.
    Puljak L.
    Am J Phys Med Rehabil; 2019 Mar 27; 98(3):245-246. PubMed ID: 30640292
    [No Abstract] [Full Text] [Related]

  • 11. Botulinum toxin type A for the treatment of migraine.
    Aurora S.
    Expert Opin Pharmacother; 2006 Jun 27; 7(8):1085-95. PubMed ID: 16722818
    [Abstract] [Full Text] [Related]

  • 12. Botox for chronic migraine.
    Drug Ther Bull; 2011 Feb 27; 49(2):22-4; quiz iii-iv. PubMed ID: 21304165
    [Abstract] [Full Text] [Related]

  • 13. Botulinum neurotoxin A for chronic migraine headaches: does it work and how?
    Cairns BE, Gazerani P.
    Pain Manag; 2014 Feb 27; 4(6):377-80. PubMed ID: 25494688
    [No Abstract] [Full Text] [Related]

  • 14. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct 27; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 15. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
    Lipton RB, Varon SF, Grosberg B, McAllister PJ, Freitag F, Aurora SK, Dodick DW, Silberstein SD, Diener HC, DeGryse RE, Nolan ME, Turkel CC.
    Neurology; 2011 Oct 11; 77(15):1465-72. PubMed ID: 21956721
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine.
    Russell MB.
    J Headache Pain; 2011 Apr 11; 12(2):135-6. PubMed ID: 21442332
    [No Abstract] [Full Text] [Related]

  • 18. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
    Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, Turkel CC.
    J Neurol Neurosurg Psychiatry; 2015 Sep 11; 86(9):996-1001. PubMed ID: 25500317
    [Abstract] [Full Text] [Related]

  • 19. Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database.
    Hepp Z, Rosen NL, Gillard PG, Varon SF, Mathew N, Dodick DW.
    Cephalalgia; 2016 Aug 11; 36(9):862-74. PubMed ID: 26692400
    [Abstract] [Full Text] [Related]

  • 20. OnabotulinumtoxinA in chronic migraine: long-term efficacy in a prophylactic medication free cohort.
    Schiano di Cola F, Pari E, Caratozzolo S, Mancinelli C, Liberini P, Rao R, Padovani A.
    Neurol Sci; 2018 Jun 11; 39(Suppl 1):159-160. PubMed ID: 29904848
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.